



HELP YOUR APPROPRIATE PATIENTS  
TAP INTO MORE SUPPORT WITH  
**DUPIXENT**  
**Patient Resources**

**Getting Started  
and Staying on Track**

**INDICATION**

DUPIXENT is indicated for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.


**IMPORTANT SAFETY INFORMATION**

**CONTRAINDICATION:** DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

**Please see additional Important Safety Information throughout and accompanying full Prescribing Information.**


## COMPLEMENTING THE CARE YOU PROVIDE

We're here to help support your appropriate patients and their caregivers throughout their treatment journey, with the DUPIXENT Patient Starter Kit and a host of digital, print, and interactive offerings.



### The DUPIXENT Patient Brochure

The DUPIXENT patient brochure helps educate patients when they are considering DUPIXENT. The brochure can help the patient evaluate their condition and provide key details about DUPIXENT and the *DUPIXENT MyWay*<sup>®</sup> Patient Support Program.



### The DUPIXENT Patient Starter Kit

The DUPIXENT Patient Starter Kit walks patients through starting treatment, including how DUPIXENT works, clinical trial results, and what they might expect from treatment. While their healthcare provider is their best source of information, the Starter Kit introduces patients to a host of *DUPIXENT MyWay* Patient Support Program resources that may be able to help at every stage of treatment, once enrolled.

## IMPORTANT SAFETY INFORMATION (cont'd)

### WARNINGS AND PRECAUTIONS

**Hypersensitivity:** Hypersensitivity reactions, including generalized urticaria, rash, erythema nodosum, erythema multiforme, anaphylaxis and serum sickness or serum sickness-like reactions, were reported in <1% of subjects who received DUPIXENT in clinical trials. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

**Please see additional Important Safety Information throughout and accompanying full Prescribing Information.**



### AN EMAIL ADDRESS UNLOCKS EVEN MORE SUPPORT

Your patients and caregivers of children and adolescents (ages 6 years and older) can provide an email address on DUPIXENT.com, or at point of prescription, in the first section of the [DUPIXENT MyWay Enrollment Form](#), for access to digital DUPIXENT patient resources.

#### **Accessing additional support resources**

DUPIXENT.com is a good place for patients and caregivers to begin but their email address unlocks exclusive website content, email updates, and interactive resources for getting started and staying on track with DUPIXENT.

## **IMPORTANT SAFETY INFORMATION (cont'd)**

**Conjunctivitis and Keratitis:** Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received DUPIXENT. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered or were recovering during the treatment period. Advise patients to report new onset or worsening eye symptoms to their healthcare provider

**Risk Associated with Abrupt Reduction of Corticosteroid Dosage:** Do not discontinue systemic, topical or inhaled corticosteroids abruptly upon initiation with DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

**Please see additional Important Safety Information throughout and accompanying full Prescribing Information.**



## GETTING STARTED

We have materials to help patients and caregivers of children and adolescents (ages 6 years and older) understand how DUPIXENT works, navigate insurance coverage, and learn more about what to expect while they wait for their first shipment.

### PATIENT SUPPORT PROGRAM

Patients and caregivers can access information about financial assistance options, including the *DUPIXENT MyWay*<sup>®</sup> Copay Card, and download the enrollment form for the *DUPIXENT MyWay* Patient Support Program at [DUPIXENT.com](https://www.dupilumab.com). Enrolled patients are assigned a Nurse Educator who can research and help explain insurance coverage information, and can provide supplemental injection training and additional education about DUPIXENT.

### EDUCATIONAL WEBINARS


FREE virtual webinars let your patients and their caregivers hear firsthand from actual DUPIXENT patients with uncontrolled moderate-to-severe eczema (atopic dermatitis). They can also see patient stories on [DUPIXENT.com](https://www.dupilumab.com).

### MOTIVATION WHILE WAITING FOR TREATMENT

Caregivers can download inspirational images and send to patients via text or email to help keep them motivated and hopeful about their upcoming treatment.



### NEXT STEPS VIDEO



For many patients, filling a prescription through a specialty pharmacy is a new experience. This video on [DUPIXENT.com](https://www.dupilumab.com) walks patients and caregivers through what to expect while waiting for the first delivery.

 = an email address must be provided to access this *DUPIXENT MyWay* exclusive content

### IMPORTANT SAFETY INFORMATION (cont'd)

**Atopic Dermatitis Patients with Comorbid Asthma:** Advise patients not to adjust or stop their asthma treatments without consultation with their physicians.

**Please see additional Important Safety Information throughout and accompanying full Prescribing Information.**




## BUILDING FAMILIARITY WITH INJECTION TRAINING

We have materials to help your patients and caregivers of children and adolescents (ages 6 years and older) become more familiar with administering DUPIXENT while addressing common barriers to adherence.

### CONNECTING WITH A MENTOR

Sometimes it helps to know you're not alone. Patients and caregivers of children and adolescents can speak with DUPIXENT Patient Mentors via phone to hear how real patients have found help managing their condition.

### MAKING A ROUTINE FOR TAKING DUPIXENT VIDEO



Establishing a routine can help patients remember to take DUPIXENT as directed. [This video](#)

discusses the value of planning ahead and offers ideas on how to build DUPIXENT into a routine.

### SUPPLEMENTAL INJECTION TRAINING



In addition to training from their healthcare provider, patients and caregivers can schedule 1-on-1 supplemental

injection training with a *DUPIXENT MyWay* Nurse Educator, over the phone or via video chat, to become more familiar with injecting DUPIXENT. The DUPIXENT Training Kit can help guide patients and caregivers through the process of beginning their new treatment routine, and [videos about how to administer DUPIXENT](#) are available on DUPIXENT.com anytime as a refresher.



### IMPORTANT SAFETY INFORMATION (cont'd)

**Parasitic (Helminth) Infections:** It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.


**Please see additional Important Safety Information throughout and accompanying full [Prescribing Information](#).**

## KEEPING MOTIVATION HIGH

We have materials to help your patients and caregivers of children and adolescents (ages 6 years and older) feel supported and stay committed throughout their treatment journey.

### MEET A NURSE EDUCATOR VIDEO

This video at DUPIXENT.com gives your patients and their caregivers a glimpse at a day in the life of a *DUPIXENT MyWay* Nurse Educator. They can see for themselves what support from *DUPIXENT MyWay* looks like.



### DUPIXENT MyWay PATIENT JOURNAL

Patients and caregivers can use this journal to organize notes from healthcare appointments, track symptoms, write down their treatment schedule, and monitor progress on treatment.

### YouTube VIDEO CONTENT



Your patients and their caregivers can see what's possible by watching videos of other patients and providers sharing their perspective on DUPIXENT.

## IMPORTANT SAFETY INFORMATION (cont'd)

**ADVERSE REACTIONS:** The most common adverse reactions (incidence  $\geq 1\%$  at Week 16) in adult patients with atopic dermatitis are injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye. The safety profile in children and adolescents through Week 16 was similar to that of adults with atopic dermatitis. In an open-label extension study, the long-term safety profile of DUPIXENT in adolescents and children observed through Week 52 was consistent with that seen in adults with atopic dermatitis.

**DRUG INTERACTIONS:** Avoid use of live vaccines in patients treated with DUPIXENT.


**Please see additional Important Safety Information throughout and accompanying full Prescribing Information.**



## PROMOTING SELF-CARE

We have materials to help support the emotional well-being of your patients and caregivers of children and adolescents (ages 6 years and older) with engaging and interactive resources.

### TAKING TIME TO REFLECT



Caregivers can find suggestions for creative ways to help patients express their thoughts and keep them moving forward on our websites.

### THE POWER OF POSITIVE THINKING

Your patients' belief in their own ability to use DUPIXENT could increase the likelihood that they'll stay on track with treatment.

### A MINDFUL BREATHING EXERCISE

Designed to help patients and their caregivers manage nervousness about injections, this audio recording encourages them to focus on their breathing and the present moment.



- Patients should **visit the sites often!** New resources specially designed to support all DUPIXENT patients and caregivers are added frequently.

## IMPORTANT SAFETY INFORMATION (cont'd)

### USE IN SPECIFIC POPULATIONS

- **Pregnancy:** A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to <https://mothertobaby.org/ongoing-study/dupixent/>. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.

**Please see additional Important Safety Information throughout and accompanying full Prescribing Information.**

## THE *DUPIXENT MyWay*® COPAY CARD

With the *DUPIXENT MyWay*® Copay Card, eligible, commercially insured patients may pay as little as a \$0\* copay per fill of *DUPIXENT*® (dupilumab), maximum of \$13,000 per patient per calendar year. And, if you're eligible, you can sign up and download your card today.

This copay card may be for you if you

- Have commercial insurance, including health insurance exchanges, federal employee plans, or state employee plans
- Have a *DUPIXENT* prescription for an FDA-approved condition
- Are a resident of the 50 United States, the District of Columbia, or Puerto Rico

\*THIS IS NOT INSURANCE. Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE, or other federal or state programs including any state pharmaceutical assistance programs. Program has an annual maximum of \$13,000. Additional terms and conditions apply.



## SIGNING UP FOR EXTRA SUPPORT

Remember that if you collect an email address at point of prescription, your patients and caregivers of children (ages 6–17 years) can receive additional support from *DUPIXENT MyWay*. They can also register\* anytime via [DUPIXENT.com](https://www.dupixent.com), or by phone at **1-844-DUPIXENT (1-844-387-4936), option 1**.

\*Registering on *DUPIXENT.com* subscribes patients and caregivers to exclusive web content, emails, and interactive resources.

## IMPORTANT SAFETY INFORMATION (cont'd)

### USE IN SPECIFIC POPULATIONS

- **Lactation:** There are no data on the presence of *DUPIXENT* in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for *DUPIXENT* and any potential adverse effects on the breastfed child from *DUPIXENT* or from the underlying maternal condition.

**Please see accompanying full Prescribing Information**

SANOFI GENZYME 

REGENERON

*DUPIXENT*® and *DUPIXENT MyWay*® are registered trademarks of Sanofi Biotechnology.  
© 2021 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.  
DUP.21.10.0316 November 2021